$DFTX Definium Therapeutics (NASDAQFTX) Stock Price Expected to Rise, HC Wainwright Analyst Says Definium Therapeutics (NASDAQFTX - Get Free Report) had its price objective hoisted by investment analysts at HC Wainwright from $55.00 to $70.00 in a research note issued on Monday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price points to a potential upside of 301.15% from the company's current price. https://www.marketbeat.com/instant-...o-rise-hc-wainwright-analyst-says-2026-03-02/
DT-402 will make $DFTX a 20B company long term after DT-120 is approved. If a treatment could improve social functioning or learning, it could potentially reduce the number of therapy hours required over time. https://www.wsj.com/health/healthca...aa435?st=DYgYyH&reflink=article_copyURL_share @WSJbusiness @WSJhealth @WSJmarkets
GOP Senator To File Bill Promoting Psychedelics Research And Treatment For Veterans https://www.marijuanamoment.net/gop...hedelics-research-and-treatment-for-veterans/
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 https://ir.definiumtx.com/news-even...-and-analyst-day-in-new-york-on-april-22-2026
Complete biosynthesis of psychedelic tryptamines from three kingdoms in plants https://www.science.org/doi/10.1126/sciadv.aeb3034 This paper is not about discovering new psychedelics. It is about controlling how they are made. The researchers produced DMT, psilocin, psilocybin, bufotenin, and 5-MeO-DMT in a plant system by rebuilding the full biosynthetic pathway. The implication is on the production side, which is where this becomes relevant for companies like $DFTX, $ATAI, and $CMPS if they are positioned anywhere along the supply or formulation chain. A lot of these compounds today still rely on complex synthesis or extraction workflows. This approach shifts production toward programmable biosynthesis. That means more consistent batches, tighter purity control, and likely a lower cost per gram at scale. As these companies move through FDA pathways, manufacturing becomes critical. Cost of goods and consistency directly impact margins, scalability, and pricing. It is not just about proving the therapy works. It is about producing it reliably at pharmaceutical grade. The takeaway here is infrastructure. Lower production costs, better control, and more flexibility in compound design all strengthen the long term commercial case for companies working to bring these therapies to market.
I interviewed the CEOs of Reddit, Colgate-Palmolive, and 6 other top companies about leading for the long run. Here’s what they said https://www.fastcompany.com/9151710...ir-advice-business-advice-leadership-long-run Rob Barrow, CEO of Definium Therapeutics “The U.S. is facing a profound and worsening mental health crisis, with current treatment options failing millions of people. Our big bet: to usher in a new era of psychiatry with the potential of lysergide tartrate, or LSD, which had its start in systematic research in the 1940s. Through the lens of modern science, our rigorous clinical trials are designed to explore and generate regulatory-grade evidence, and we believe we’re approaching a meaningful shift in what mental health treatment could look like. This will require deep education and collaboration across many stakeholders to create lasting change, but we’re excited and emboldened by the opportunity.”
Psychedelics Executive Order — News Coverage Roundup The Washington Post Trump orders more access to psychedelics like LSD, psilocybin and ibogaine https://www.washingtonpost.com/politics/2026/04/17/trump-psychedelics-psylocibin-research/ Pittsburgh Post-Gazette Trump signs order to speed review of psychedelics, including the controversial drug ibogaine https://www.post-gazette.com/news/p...-drugs-ibogaine-veterans/stories/202604180045 WSAZ President Trump signs executive order encouraging research on psychedelic drugs https://www.wsaz.com/2026/04/18/pre...order-encouraging-research-psychedelic-drugs/ CNN Trump accelerates research on psychedelic treatments and asks, ‘Can I have some?’ https://www.cnn.com/2026/04/18/poli...rging-more-research-into-psychedelic-ibogaine MS NOW Trump signs executive order on psychedelic drugs — with Joe Rogan by his side https://www.ms.now/news/trump-executive-order-psychedelic-drugs-joe-rogan The Guardian Trump announces reforms to accelerate access to psychedelic drug treatments https://www.theguardian.com/us-news/2026/apr/18/trump-psychedelic-drugs-executive-order USA Today Trump signs order pushing psychedelics research after Joe Rogan call https://www.usatoday.com/story/news...ive-order-psychedelics-joe-rogan/89676816007/ Reuters Trump signs order to accelerate access to psychedelic drug treatments https://www.reuters.com/world/trump...ccess-psychedelic-drug-treatments-2026-04-18/ Bloomberg Trump Signs Order on Psychedelics to Ease FDA Restrictions https://www.bloomberg.com/news/arti...rder-easing-restrictions-on-psychedelic-drugs The Wall Street Journal How Joe Rogan Convinced Trump to Fast-Track Review of Psychedelic Drugs https://www.wsj.com/politics/policy...st-track-review-of-psychedelic-drugs-3618fd73
ABC News - Trump signs executive order to accelerate research of psychedelic-based drugs Interview with Martin MaKary
President Trump’s Landmark Order Advances Breakthrough Mental Health Treatments — Delivering New Hope to Veterans https://www.whitehouse.gov/releases...h-treatments-delivering-new-hope-to-veterans/ --- DFTX Mention --- Definium Therapeutics CEO Rob Barrow: “Accelerating scientific progress depends on both rigor and urgency, and we thank the Administration and welcome this Executive Order as an important recognition of the persistent unmet treatment needs in serious mental illness. We applaud the Administration’s recognition that psychedelic medicines may represent meaningful new treatment options for patients. We are advancing a comprehensive clinical development program for DT120 (lysergide tartrate) for millions of patients living with conditions including generalized anxiety disorder (GAD) and major depressive disorder (MDD). A science-driven framework that supports rigorous evaluation, responsible access, and faster translation of innovation into care is essential, and the FDA’s evidence-based approval process provides the most effective path to safely delivering these therapies to patients. We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have.”
Investor & Analyst Day Date: Wednesday, April 22, 2026 Time: 10:00 am – 12:00 pm ET, followed by lunch Location: Virtual Link below https://definium-therapeutics-investor-analyst-day-2026.open-exchange.net/registration
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day April 22, 2026 4:15pm EDT https://ir.definiumtx.com/news-even...mmercial-strategy-at-investor-and-analyst-day MDD: Emerge topline data readout on track for late 2Q 2026; Ascend sites activated with first patient dosing anticipated in 2Q 2026 GAD: Voyage enrollment complete with 214 patients with topline data readout on track for early 3Q 2026; Panorama sample size re-estimation complete and target sample size updated to 200; screening closed with topline readout now expected in late 3Q 2026 PTSD: DT120 ODT program expanded into PTSD with Phase 3 Haven study expected to initiate in 2027
Accelerated FDA Action for Psychedelics: Insights From Daniel R. Karlin, MD, MA Author(s)Daniel R. Karlin, MD, MA Definium’s CMO says FDA talks stay aligned with their plans for advancing DT120 ODT for the treatment of depression, anxiety, and now PTSD. https://www.psychiatrictimes.com/vi...chedelics-insights-from-daniel-r-karlin-md-ma
The Latest Data on Psychedelic DT120 ODT With Daniel R. Karlin, MD, MA Videos|April 27, 2026 https://www.psychiatrictimes.com/vi...chedelic-dt120-odt-with-daniel-r-karlin-md-ma Daniel R. Karlin, MD, MA, the chief medical officer of Definium Therapeutics, shared some more information about the data on DT120 and what separates it from other psychedelics, including the new information shared at their Investor and Analyst Day.
Watch May 19th at 8:30AM EST - Rethinking Psychedelic Treatment for America's Mental Health Crisis Psychiatry is at an inflection point. And the stakes are high. Mental illness costs the U.S. economy more than $280 billion annually, drives veteran suicide rates, and places mounting strain on everything from emergency rooms to the workforce. Yet many of today’s medicines have not advanced in decades despite the rising prevalence and unmet need. For the one in five Americans living with a mental health disorder and veterans who face disproportionally high suicide rates and do not respond to conventional treatments, the gap between what medicine promises and what it delivers has never been more consequential. But change is underway. A new wave of rigorous clinical science is unlocking the therapeutic potential of psychedelic medicines and opening new routes for brain health that could redefine what treatment success looks like. Psychedelic medicines are advancing through late-stage clinical trials, with several investigational candidates earning FDA Breakthrough Therapy Designation for disorders including anxiety and depression. Join The Hill, in partnership with Definium Therapeutics, for a timely mental health policy forum convening lawmakers, clinical researchers, and advocates to explore what science tells us, what the regulatory landscape requires, and what actions Congress can take to ensure that patients are not left behind.
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder https://www.businesswire.com/news/h...udy-of-DT120-ODT-in-Major-Depressive-Disorder The primary endpoint will measure the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between DT120 Orally Disintegrating Tablet (ODT) 100 µg and placebo Ascend builds on positive Phase 2b study results in generalized anxiety disorder, which showed the potential antidepressant effects of DT120 Topline data from the 12-week double-blind period is anticipated in 2027
Americans are increasingly open to using psychedelics for medical reasons https://www.scientificamerican.com/...en-to-using-psychedelics-for-medical-reasons/
Is this finally the breakthrough moment for psychedelic therapies? https://www.rbccm.com/en/insights/2...breakthrough-moment-for-psychedelic-therapies Psychedelics may finally be close to mainstream medical use, but is the healthcare system prepared for mass delivery to patients? Hosted By Joseph Coletti Featuring Brian Abrahams and Leonid Timashev Published May 22, 2026 Key points Patient and physician interest and favorable regulation signal an imminent breakthrough for psychedelics to treat mental ill-health. April’s Presidential order on accelerated research and access for veterans with PTSD is also supportive. Psychedelics raise challenges for clinical trials, but companies are finding ways to overcome these. RBC’s research indicates existing clinic infrastructure is equipped to deliver psychedelics with the required clinical supervision.
